H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $32 from $55 and keeps a Buy rating on the shares. The firm cites share dilution from the capital raise and adjustments to reflect the company’s opportunity in Sjogren’s disease for the target cut.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: